MabThera was the first therapeutic monoclonal antibody to target cells that have the CD20 marker on their surface. These cells are central to many blood cancers, including common forms of lymphoma and leukaemia. MabThera attacks these cells both directly and together with the body’s immune system.
In the United States, Europe and in other countries, MabThera is approved for the treatment of adults with the following blood cancers: previously untreated and relapsed/refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and relapsed/refractory chronic lymphocytic leukaemia. MabThera is also approved for the treatment of adults in auto-immune diseases: severe active rheumatoid arthritis, pemphigus vulgaris and severe active granulomatosis with polyangiitis and microscopic polyangiitis (GPA/MPA).
In Europe, MabThera has recently been approved in paediatric indications in GPA/MPA patients for induction of remission and previously untreated B-NHL, in combination with chemotherapy.
In the United States, Japan and Canada, MabThera is marketed as Rituxan.